TScan Therapeutics Statistics
Total Valuation
TCRX has a market cap or net worth of $90.80 million. The enterprise value is -$30.55 million.
Important Dates
The next estimated earnings date is Tuesday, November 11, 2025, before market open.
| Earnings Date | Nov 11, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
TCRX has 56.75 million shares outstanding. The number of shares has increased by 7.21% in one year.
| Current Share Class | 52.47M |
| Shares Outstanding | 56.75M |
| Shares Change (YoY) | +7.21% |
| Shares Change (QoQ) | +0.28% |
| Owned by Insiders (%) | 0.76% |
| Owned by Institutions (%) | 53.48% |
| Float | 44.03M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 13.04 |
| Forward PS | 11.93 |
| PB Ratio | 0.51 |
| P/TBV Ratio | 0.51 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.06, with a Debt / Equity ratio of 0.55.
| Current Ratio | 7.06 |
| Quick Ratio | 6.96 |
| Debt / Equity | 0.55 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -46.38 |
Financial Efficiency
Return on equity (ROE) is -63.33% and return on invested capital (ROIC) is -29.09%.
| Return on Equity (ROE) | -63.33% |
| Return on Assets (ROA) | -26.77% |
| Return on Invested Capital (ROIC) | -29.09% |
| Return on Capital Employed (ROCE) | -53.97% |
| Revenue Per Employee | $35,697 |
| Profits Per Employee | -$701,410 |
| Employee Count | 195 |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -72.13% in the last 52 weeks. The beta is 0.99, so TCRX's price volatility has been similar to the market average.
| Beta (5Y) | 0.99 |
| 52-Week Price Change | -72.13% |
| 50-Day Moving Average | 1.79 |
| 200-Day Moving Average | 1.99 |
| Relative Strength Index (RSI) | 36.40 |
| Average Volume (20 Days) | 228,843 |
Short Selling Information
The latest short interest is 1.71 million, so 3.02% of the outstanding shares have been sold short.
| Short Interest | 1.71M |
| Short Previous Month | 1.85M |
| Short % of Shares Out | 3.02% |
| Short % of Float | 3.89% |
| Short Ratio (days to cover) | 7.61 |
Income Statement
In the last 12 months, TCRX had revenue of $6.96 million and -$136.78 million in losses. Loss per share was -$2.41.
| Revenue | 6.96M |
| Gross Profit | -8.57M |
| Operating Income | -144.24M |
| Pretax Income | -96.80M |
| Net Income | -136.78M |
| EBITDA | -141.12M |
| EBIT | -144.24M |
| Loss Per Share | -$2.41 |
Full Income StatementBalance Sheet
The company has $218.05 million in cash and $96.70 million in debt, giving a net cash position of $121.35 million or $2.14 per share.
| Cash & Cash Equivalents | 218.05M |
| Total Debt | 96.70M |
| Net Cash | 121.35M |
| Net Cash Per Share | $2.14 |
| Equity (Book Value) | 176.71M |
| Book Value Per Share | 3.11 |
| Working Capital | 189.81M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$126.18 million and capital expenditures -$5.07 million, giving a free cash flow of -$131.25 million.
| Operating Cash Flow | -126.18M |
| Capital Expenditures | -5.07M |
| Free Cash Flow | -131.25M |
| FCF Per Share | -$2.31 |
Full Cash Flow StatementMargins
| Gross Margin | -123.16% |
| Operating Margin | -2,072.07% |
| Pretax Margin | -1,964.88% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
TCRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -7.21% |
| Shareholder Yield | -7.21% |
| Earnings Yield | -150.64% |
| FCF Yield | -144.56% |
Analyst Forecast
The average price target for TCRX is $9.40, which is 487.50% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $9.40 |
| Price Target Difference | 487.50% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | 109.83% |
| EPS Growth Forecast (5Y) | -21.15% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
TCRX has an Altman Z-Score of -1.94 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.94 |
| Piotroski F-Score | 1 |
